Marker Therapeutics vs Xenetic Biosciences
MRKR and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRKR and XBIO compare
Marker Therapeutics is the larger company, worth 3.7 times as much as Xenetic Biosciences ($14.5M against $3.9M).
Xenetic Biosciences scores higher on the StockData Score (10 against 6 for Marker Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRKR | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $14.5M | $3.9M |
| Share price | $0.870 | $1.66 |
| Change, 1 year | −7.8% | −37.1% |
| Change, 5 years | −93.3% | −88.8% |
| Beta (5Y) | 1.27 | 0.87 |
| Employees | 5 | 2 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.3× |
| P/B | 1.2× | 0.9× (better) |
| Fair value | – | $3.65 |
| Margin of safety | – | 54.5% |
| Growth | ||
| Revenue growth (TTM) | – | 3.5% |
| Revenue growth, 5Y average | 48.0% (better) | 46.8% |
| Profitability | ||
| Operating margin | – | −130% |
| Net margin | – | −124% |
| Return on equity | −76.9% (better) | −87.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.03 (better) | 3.15 |
| Altman Z-score | −42.38 (better) | −44.51 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 23.8% | 6.5% |
| Held by insiders | 31.9% | 12.2% |
| Short interest, % of float | 1.6% | 1.8% |
Go deeper
- MRKR stock overview
- MRKR income statement
- MRKR valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.